Related Experiment Video
Updated: Feb 18, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Cancer stem cell-like population is preferentially suppressed by EGFR-TKIs in EGFR-mutated PC-9 tumor models
1Department of Immunology, Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Huanhuxi Road, Tiyuanbei, Hexi District, Tianjin 300060, People's Republic of China; Sichuan Lung Cancer Institute, Sichuan Lung Cancer Center, West China School of Medicine/West China Hospital, Sichuan University, No.37 Guoxue Lane, Wuhou District, Chengdu 610041, People's Republic of China; Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, No.154 Anshan Street, Heping District, Tianjin 300052, People's Republic of China.
Aims:
Although the epidermal growth factor receptor (EGFR) and Wnt/β-catenin signaling systems synergistically regulate many essential developmental and regenerative processes in lung cancer, the mechanisms of their crosstalk remain poorly defined. Our study aimed to investigate an interaction between EGFR and the β-catenin signal.
Results:
In this study, we described a potent activation of β-catenin by EGFR, which is dependent of the PtdIns3K/AKT pathway. We found EGF activated β-catenin signaling via phosphorylation of EGFR and AKT in EGFR-mutated PC-9 lung cancer cells. Meanwhile, EGFR tyrosine kinase inhibitors (EGFR-TKIs) regulated cancer stem-like cells (CSCs) by inhibiting autophosphorylation of EGFR and downstream signaling proteins, as well as β-catenin. Further, β-catenin depletion by RNA interference virtually eliminated cancer stem cell-like population in PC-9 cells in vitro. The nude mice transplantation model was also performed to confirm EGFR-TKIs strongly inhibited the β-catenin signal and decreased CSCs. Importantly, the reduction of CSCs that sorted out by side population (SP) cells significantly reduced the migration capability. Thus, our results improved the understanding of this process to provide insights into mechanisms of responding to EGFR-TKIs.
Conclusions:
Our discoveries raise an intriguing question of the role of β-catenin in EGFR-TKIs-treated cancer stem cell-like population(s) and its potential as a new therapeutic target for NSCLC in the future.
Insights
Epidermal growth factor receptor (EGFR) activates β-catenin signaling, a key pathway in lung cancer. EGFR inhibitors reduce cancer stem cells by targeting this interaction, offering new therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling Pathways
Background:
- Epidermal growth factor receptor (EGFR) and Wnt/β-catenin signaling are crucial for lung cancer development and regeneration.
- The precise mechanisms of crosstalk between EGFR and β-catenin signaling are not fully understood.
Purpose of the Study:
- To investigate the interaction between EGFR and the β-catenin signaling pathway.
- To explore the role of this crosstalk in lung cancer, particularly in EGFR-mutated cells.
Main Methods:
- Utilized EGFR-mutated PC-9 lung cancer cells.
- Investigated the role of the PtdIns3K/AKT pathway in EGFR-mediated β-catenin activation.
- Employed EGFR tyrosine kinase inhibitors (EGFR-TKIs) and RNA interference for β-catenin depletion.
- Used a nude mice transplantation model and side population (SP) cell sorting.
Main Results:
- EGFR activation leads to potent β-catenin activation, dependent on the PtdIns3K/AKT pathway.
- EGFR-TKIs inhibit EGFR autophosphorylation, downstream signaling, and β-catenin, reducing cancer stem-like cells (CSCs).
- β-catenin depletion significantly reduced CSCs in vitro and in vivo, decreasing tumor cell migration.
Conclusions:
- EGFR signaling potently activates β-catenin in lung cancer cells.
- Targeting β-catenin in combination with EGFR-TKIs may be a promising therapeutic strategy for non-small cell lung cancer (NSCLC).
- Further research into β-catenin's role in EGFR-TKI treatment resistance is warranted.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Mitogens and the Cell Cycle